Quest Diagnostics traces its origins to a small pathology laboratory founded in 1967 by Dr. Paul A. Brown in Teaneck, New Jersey. Brown, a pathologist, established Metropolitan Pathology Laboratory, Inc. to provide clinical laboratory services to local physicians and hospitals. In 1969, the company changed its name to MetPath, Inc., and by the early 1980s had grown into a significant regional laboratory operation. The pivotal moment in Quest's early history came in 1982 when Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. Corning, a diversified materials science company, saw clinical laboratory services as a growth opportunity within its healthcare portfolio. Under Corning's ownership, the laboratory business expanded through internal growth and small acquisitions, but it remained a relatively small division within the larger Corning enterprise. On December 31, 1996, Quest Diagnostics became an independent company through a spin-off from Corning. Kenneth W. Freeman was appointed CEO of the newly independent entity, which began trading on the New York Stock Exchange under ticker DGX. The spin-off gave Quest the strategic flexibility and capital allocation autonomy to pursue an aggressive acquisition strategy that would transform the company. The first major acquisition came in 1997 when Quest acquired the clinical laboratory division of Diagnostic Medical Laboratory, Inc. (DML) based in Branford, Connecticut. But the transformative deal was the 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL) for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in revenue in 1998 and added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and—uniquely—a medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) founded in 1988. The acquisition made Quest the clear industry leader in diagnostic testing and doubled the company's size. SmithKline Beecham received approximately $1.0 billion in cash and 12.6 million newly issued shares, holding approximately 29% of Quest's outstanding stock post-transaction. The 2000s brought continued expansion. In 2001, Quest acquired MedPlus, Inc., a healthcare technology company. In 2002, the company acquired American Medical Laboratories, Inc. (AML) and LabPortal, Inc. for $500 million. In 2003, Quest acquired Unilab Corporation for $800 million, significantly expanding its West Coast presence. The Unilab acquisition required divestiture of certain Northern California assets to LabCorp for $4.5 million to satisfy antitrust concerns. In 2005, Quest acquired LabOne, Inc. for $934 million, adding employer drug testing and paramedical testing capabilities. In 2006, the company acquired Focus Diagnostics for $185 million, strengthening infectious and immunologic disease testing. In 2007, Quest made two significant acquisitions: Hemocue (point-of-care diagnostic testing, Sweden) and AmeriPath (cancer diagnostic testing) for approximately $1.23 billion. The AmeriPath acquisition added anatomic pathology capabilities and specialty laboratory services that complemented Quest's clinical chemistry strengths. From May 2004 to April 2012, Surya Mohapatra served as President and CEO. Mohapatra expanded Quest's international presence and technology capabilities but faced challenges during the 2008-2009 financial crisis when diagnostic testing volumes declined as patients deferred non-urgent care. In 2011, Quest acquired Athena Diagnostics (neurodegenerative disease testing) and Celera Corporation (genomics and sequencing), adding advanced diagnostics capabilities. In 2012, Steve Rusckowski, former CEO of Philips Healthcare, was appointed CEO, succeeding Mohapatra. Rusckowski led a decade-long transformation focused on operational excellence, health system partnerships, and growth initiatives. Under Rusckowski, Quest formed strategic laboratory partnerships with UMass Memorial Health Care (2013), Barnabas Health (2015), and numerous other health systems. In 2014, Quest acquired Solstas Lab Partners Group for $570 million and Summit Health, expanding its geographic footprint in the Southeast. In 2016, Quest collaborated with Safeway to bring testing services to 12 stores. In 2017, the company partnered with Walmart to incorporate laboratory testing in approximately 15 locations. In 2018, Quest became an in-network laboratory provider to UnitedHealthcare, gaining access to 48 million plan members. In September 2018, the company moved its headquarters from Madison, New Jersey to Secaucus, New Jersey. In November 2018, Quest launched QuestDirect, its consumer-initiated testing service. The COVID-19 pandemic in 2020-2021 created both challenge and opportunity. Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. The pandemic testing demand generated substantial revenue and profits but also created operational complexity and workforce strain. CEO Rusckowski became deeply involved in the national pandemic response, partnering with elected officials, public health authorities, and healthcare providers to expand testing access. In 2020, Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases. In 2020-2021, the company acquired outreach laboratory operations from Memorial Hermann Health System and Hackensack Meridian Health. In 2021, Quest acquired Mercy's outreach laboratory services business. In 2023, the company acquired Haystack Oncology, a minimal residual disease testing company, and the outreach operations of NewYork-Presbyterian Hospital for $275 million. In February 2022, the board announced that Jim Davis, then Executive Vice President of General Diagnostics, would succeed Rusckowski as CEO. Davis assumed the role on November 1, 2022, and became Chairman on April 1, 2023. Davis brought a distinctive background: before joining Quest in 2013, he had been CEO of InSightec (a medical device company), held senior management positions at GE's aviation and healthcare businesses (including leading GE's MRI business for five years), and worked at McKinsey & Company. He holds master's degrees from MIT Sloan School of Management and MIT, plus a bachelor's in aeronautical engineering from the University of Michigan. Under Davis, Quest has accelerated its acquisition strategy and advanced diagnostics focus. In 2024, the company acquired select assets of Steward Health Care System's outreach lab business, Lenco Diagnostic Laboratories in Brooklyn, and—most significantly—LifeLabs from OMERS for CAD $1.35 billion. In 2025, Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients.